Nirsevimab Administration and RSV Hospitalization in the 2024-2025 Season
This cohort study examines rates of hospitalization associated with respiratory syncytial virus (RSV) among infants by nirsevimab administration during the 2024-2025 season.
Authors
- Michael L. Forbes (ORCID: https://orcid.org/0000-0002-8578-3432)
- Danielle Maholtz (ORCID: https://orcid.org/0000-0002-1834-8756)
- Todd Karsies (ORCID: https://orcid.org/0000-0001-6822-6952)
- Michael T. Bigham (ORCID: https://orcid.org/0000-0002-5085-2231)
- Eric D. Robinette
- Jonathan H. Pelletier (ORCID: https://orcid.org/0000-0003-1942-042X)
- Christopher M. Horvat (ORCID: https://orcid.org/0000-0002-1593-2252)
- Sarah Rush (ORCID: https://orcid.org/0000-0002-3416-7031)
- Steven L. Shein (ORCID: https://orcid.org/0000-0003-3382-5159)
Institutions
- Nationwide Children's Hospital (US)
- Akron Children's Hospital (US)
- Children's Hospital of Pittsburgh (US)
- Rainbow Babies & Children's Hospital (US)
- Northeast Ohio Medical University (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-09-24
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.33535
- Citations
- 4
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 5.42